

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>BL-F Internal request:</p> <p>Panel discussion to consider in the context of a BCG shortage the inclusion of intravesical epirubicin for induction therapy.</p>	<p>The panel consensus was to include intravesical epirubicin as an option for induction therapy when there is a BCG shortage. This is a category 2A recommendation.</p>	15	0	0	17
<p>BL-F Internal request:</p> <p>Panel discussion to consider in the context of a BCG shortage the inclusion of intravesical valrubicin for induction therapy.</p>	<p>The panel consensus was to include intravesical valrubicin as an option for induction therapy when there is a BCG shortage. This is a category 2A recommendation.</p>	15	0	0	17
<p>BL-F Internal request:</p> <p>Panel discussion to consider in the context of a BCG shortage the inclusion of intravesical docetaxel for induction therapy.</p>	<p>The panel consensus was to include intravesical docetaxel as an option for induction therapy when there is a BCG shortage. This is a category 2A recommendation.</p>	15	0	0	17
<p>BL-F Internal request:</p> <p>Panel discussion to consider in the context of a BCG shortage the inclusion of intravesical gemcitabine/docetaxel for induction therapy.</p>	<p>The panel consensus was to include intravesical gemcitabine/docetaxel as an option for induction therapy when there is a BCG shortage. This is a category 2A recommendation.</p>	15	0	0	17
<p>BL-F Internal request:</p> <p>Panel discussion to consider in the context of a BCG shortage the inclusion of intravesical gemcitabine/mitomycin for induction therapy.</p>	<p>The panel consensus was to include intravesical gemcitabine/mitomycin as an option for induction therapy when there is a BCG shortage. This is a category 2A recommendation.</p>	15	0	0	17